Clinical Trial Update: Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study [Phase 1, Phase 2]

View source ↗

Summary

This Phase 1/2 trial evaluated adding bortezomib to high-dose melphalan followed by autologous peripheral blood stem cell transplant in multiple myeloma to find…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Melphalan (Melphalan)

Snippet

Sponsor: Emory University | Conditions: Cancer, Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2012-06-18